Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma

NCT02679196 is registered in ClinicalTrials.gov with Karus Therapeutics Limited as lead sponsor.

NCT NCT02679196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02679196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma
Lead sponsor
Karus Therapeutics Limited
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2016
Completion date
December 24, 2018
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b cell